Oligonucleotide Inhibits miR-132 for Heart Failure Treatment
Summary
USPTO granted patent US12600964B2 to Medizinische Hochschule Hannover for an oligonucleotide inhibitor of microRNA miR-132 for treatment of cardiac and/or fibrotic disorders. The patent names Thomas Thum, Sandor Batkai, and Ariana Foinquinos as inventors. Three claims were allowed with filing date November 17, 2021.
What changed
USPTO granted patent US12600964B2 for an oligonucleotide composition effective as an inhibitor of microRNA miR-132. The invention relates to the use of this compound in medicine, specifically for prevention or treatment of cardiac disorders and fibrotic conditions.
For parties in the biotechnology and pharmaceutical sectors engaged in RNA-based therapeutics or cardiovascular drug development, this patent establishes intellectual property protection for miR-132 inhibition technology. Organizations developing similar microRNA-targeted therapies should conduct freedom-to-operate analyses to assess potential licensing needs.
What to do next
- Monitor for updates
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compound for treatment of heart failure
Grant US12600964B2 Kind: B2 Apr 14, 2026
Assignee
Medizinische Hochschule Hannover
Inventors
Thomas Thum, Sandor Batkai, Ariana Foinquinos
Abstract
The present invention refers to an oligonucleotide which is an effective inhibitor of microRNA miR-132 and its use in medicine, particularly in the prevention or treatment of cardiac and/or fibrotic disorders.
CPC Classifications
C12N 15/11 C12N 2310/315 C12N 2310/3231
Filing Date
2021-11-17
Application No.
17529119
Claims
3
Related changes
Get daily alerts for USPTO Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.